As we all know, JAK-STAT signaling pathway is a key mediator underlying the immunopathogenesis of psoriasis, and its presence in our psoriasis-specific differential gene enrichment results provides a new piece of evidence that drugs targeting the JAK-STAT pathway for the treatment of psoriasis although they are still in the early stages of development (22, 23). This evidence concerns the gene SOAT1 and psoriasis.